Is the individualised forecasting of the course of Alzheimer’s disease in each patient an impossible task? Not necessarily! A model developed by Stanley Durrleman and his Aramis joint-project team (Inria, CNRS, INSERM, Sorbonne Université), located at the Paris Brain Institute (ICM), has proven its worth once more. It could help to enhance the selection of patients in clinical trials and thus facilitate the emergence of new treatments.
Is the individualised forecasting of the course of Alzheimer’s disease in each patient an impossible task? Not necessarily! A model developed by Stanley Durrleman and his Aramis joint-project team (Inria, CNRS, INSERM, Sorbonne Université), located at the Paris Brain Institute (ICM), has proven its worth once more. It could help to enhance the selection of patients in clinical trials and thus facilitate the emergence of new treatments.